NCT03982485View on ClinicalTrials.gov

Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

March 29, 2023

Study Completion Date

March 29, 2031

Conditions
Breast Cancer
Interventions
DRUG

Apatinib

Apatinib 250mg, Oral, day 2,3,4,5,6,7, every week

DRUG

Paclitaxel

Paclitaxel 80mg/m2, Intravenous, day 1, 8, 15, 22, every 28 days for a cycle

DRUG

Cisplatin

Cisplatin 25mg/m2, Intravenous, day 1, 8, 15, every 28 days for a cycle

PROCEDURE

Surgery

Surgery

Trial Locations (1)

200127

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT03982485 - Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer | Biotech Hunter | Biotech Hunter